Navigation Links
Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
Date:12/20/2007

NEW YORK, Dec. 20 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (ITI), today announced it has initiated a sleep maintenance insomnia (SMI) Phase 2 clinical study using its drug candidate ITI-722. ITI-722 acts predominantly as a selective 5-HT2A receptor antagonist and represents an important new approach to the treatment of SMI. Because of its novel separation of 5-HT2A and dopamine receptor modulatory activities, ITI believes, ITI-722 can be used not only to treat SMI but it may be highly appropriate for the treatment of sleep disorders that accompany neurodegenerative disorders, including Parkinson's disease and other psychiatric disorders.

"The progression of ITI-722 into Phase 2 for SMI represents the advancement of this important new class of therapeutics," stated Sharon Mates, Ph.D., Chairman and Chief Executive Officer of Intra-Cellular Therapies. "This drug candidate has therapeutic potential to treat SMI in the general population, and in other patient populations who have been underserved, particularly peri- and post-menopausal women, and in other disorders where insomnia is a problem, including osteoarthritis, depression, Parkinson's disease and other neurologic and psychiatric disorders."

The Phase 2 program is a multi-center, randomized, double-blind placebo- controlled study in patients with SMI. The primary endpoint is an assessment of objective slow wave sleep using polysomnography (PSG). Secondary endpoints include other objective and subjective measures of SMI and sleep efficiency. Additionally, the study will make an assessment regarding next-day cognitive performance.

ITI-722 is a low-dose formulation of ITI-007, ITI's first-in-class 5-HT2A antagonist/ dopamine receptor protein phosphorylation modulator (DPPM), presently in clinical trials for the treatment of schizophrenia.

About Sleep Maintenance Disorders

From nightmares to insomnia to sleep apnea, sleep disorders disrupt the sleep of millions of peopl
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
2. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
3. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
4. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
7. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
8. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
9. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
10. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year 2015 results on Thursday, January 22, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
(Date:12/17/2014)... and SAN DIEGO , Dec. 17, 2014 ... ; AEX: PHIA) and Volcano Corporation (NASDAQ: VOLC ... for cardiovascular applications, today announced that they have entered into ... commence a tender offer to acquire all of the issued ... or a total equity purchase price of USD 1 billion ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8
... NEWARK, N.J., April 6, 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, ... that the New York Stock Exchange (the "NYSE") has notified ... rules due to the Company,s failure to timely file its ... Commission. Under NYSE rules, when a Company ...
... Par Pharmaceutical Companies, Inc. (NYSE: PRX ... of modafinil tablets, a generic version of Teva,s Provigil® ... the Provigil® product.  Par acquired the U.S. marketing rights ... of Cephalon in 2011.  According to IMS Health data, ...
Cached Medicine Technology:American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard 2Par Pharmaceutical Begins Shipment of Generic Provigil® 2
(Date:12/20/2014)... December 21, 2014 MissyDress, a distinguished ... all prom lovers. The business has drastically cut prices ... dresses to everyone until Jan. 30, 2015. Many of ... sweetheart dresses, V-neck dresses, lace dresses, and more. , ... not there every day. Whether A-line princess prom dresses ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The print ... Post, with a distribution of approximately 160,000 copies and ... distributed nationally through a vast social media strategy and ... outlets. To explore the digital version of the campaign, ... exclusive interview with the ladies of CTV’s The ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 As ... move forward in U.S. courts, Bernstein Liebhard LLP ... suggests that children treated with the medication may ... to breast development and lactation. The study, which ... children and adolescents who began treatment with risperidone, ...
(Date:12/20/2014)... December 20, 2014 Xarelto bleeding ... suffered uncontrollable bleeding and other serious side effects ... District of Louisiana for coordinated pretrial proceedings, Wright &amp;amp; ... Litigation (JPML) issued an order Friday to transfer 21 ... in 22 federal courts to the Louisiana district court ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with the holidays and ... wayside until Christmas and the New Year are over. However, ... burning desire to just escape it all and get away, ... with a no-fuss, affordable package. Montrose Days Inn will book ... ensure that all accommodations are met. Plus, everyone has a ...
Breaking Medicine News(10 mins):Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2
... stock was ... $3.81 per share, IRVINE, Calif., Feb. ... received a letter, dated February 4,2008, from The NASDAQ Stock Market, notifying ... price of the,Company,s common stock had been below the $1.00 minimum bid ...
... standard, invasive method , , TUESDAY, Feb. 5 (HealthDay News) -- ... spread may be better than traditional, invasive procedures. , Although ... Journal of the American Medical Association , needs to ... people with lung cancer or suspected lung cancer. , "Currently, ...
... - A Road Taken Together, NORTH ADAMS, ... groups across the globe will join the National,Patient ... Week,March 2-8. The theme of the week, Patient ... for safer health care through partnership,among providers, patients, ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), ... announced today that it has signed a,definitive agreement ... Home,Health Care Affiliates, Inc. and certain of its ... subject to post-closing adjustments., The transaction will ...
... suggests that a minimally invasive approach may accurately determine ... study in the February 6 issue of JAMA. , ... death in the United States. Determining the stage of ... prognosis, according to background information in the article. ...
... - ... - Special Items Reduce Net Income by $17.9 ... ), a world leader in products and technologies to,treat advanced cardiovascular disease, ... million, or $0.27 per diluted,share, compared to net income of $20.7 million, ...
Cached Medicine News:Health News:IDM Pharma Receives Notification from NASDAQ Relating to Minimum Bid Price 2Health News:Less Invasive Way to Stage Lung Cancer Shows Promise 2Health News:Less Invasive Way to Stage Lung Cancer Shows Promise 3Health News:Patient Safety Awareness Week March 2 to March 8, 2008 2Health News:Gentiva(R) Health Services Agrees to Acquire Major Home Health Provider in CON State of Mississippi 2Health News:Gentiva(R) Health Services Agrees to Acquire Major Home Health Provider in CON State of Mississippi 3Health News:Gentiva(R) Health Services Agrees to Acquire Major Home Health Provider in CON State of Mississippi 4Health News:Less invasive methods may provide accurate means to determine lung cancer stage 2Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 2Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 3Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 4Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 5Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 6Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 7Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 8Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 9Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 10Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 11Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 12Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 13Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 14Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 15Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 16Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 17
... This compact system provides an ... preparation in the laboratory, satellite lab ... proven HEMA-TEK staining method with wedge-smear ... delivers complete standardization in a safe ...
It is a cardio-pulmonary exercise testing device....
... has digitally-controlled drive system which eliminates ... can wear out. There are no ... and fewer drive belts - resulting ... It can carry weights up to ...
... systems feature our internationally-acclaimed algorithm that ... algorithm has a proven record for ... situations; and it's just one of ... recognized market leader in the stress ...
Medicine Products: